MCAM and neoplasm: With the median expression level of the corresponding probe set across all tumors as the cutoff point for defining a rich or poor tumor for CD146, CD146-rich tumors were more frequently grade III, ER-negative or PR-negative, and displayed a basal phenotype in 41% of cases versus 22% for CD146-poor tumors (Table 1).